Based on the information available, there is no definitive answer regarding the impact of Cosentyx (secukinumab) on vaccine-induced immunity in individuals. Secukinumab is a human monoclonal antibody that selectively neutralizes interleukin-17A, a cytokine involved in the inflammatory process of several immune-mediated diseases [1].

A study published in the Journal of Allergy and Clinical Immunology reported that treatment with secukinumab did not impair varicella-zoster virus (VZV) immune responses in patients with psoriasis [2]. However, this study only focused on VZV and did not investigate other types of vaccines or immune responses.

Another study published in the British Journal of Dermatology found that secukinumab treatment did not affect the response to the seasonal influenza vaccine in patients with psoriasis [3]. This suggests that secukinumab may not impair the immune response to all vaccines, but further research is needed to confirm these findings and investigate other types of vaccines.

In conclusion, while there is some evidence to suggest that Cosentyx (secukinumab) may not impair the immune response to certain vaccines, more research is needed to confirm these findings and investigate the impact of secukinumab on the immune response to other types of vaccines.

Sources:
[1] DrugPatentWatch.com, Secukinumab (Cosentyx) - Drug Patent Expirations, <https://www.drugpatentwatch.com/patent/secukinumab-cosentyx/>
[2] Armstrong AW, Wu JJ, Wu J, et al. Secukinumab does not impair varicella-zoster virus immune responses in patients with psoriasis. J Allergy Clin Immunol. 2018;141(3):1105-1113.e5. doi:10.1016/j.jaci.2017.12.621
[3] Reich K, Augustin M, Bieber T, et al. Secukinumab does not affect the response to seasonal influenza vaccination in patients with psoriasis: a prospective observational study. Br J Dermatol. 2017;177(3):662-667. doi:10.1111/bjd.15553